available under a softgel capsule dosage form in Canada. Building on Marius’s earlier submission to Health Canada in July 2024, the company is now poised to provide Canadian men and their healthcare providers with an additional treatment option....
Kasei continues to invest in expanding its Planova™ business to meet the growing needs of the biologics market. In May 2024, the company started operation of a new assembly plant for Planova™ filters in Nobeoka City, Miyazaki, Japan, and on...
obeticholic acid and 266 used Livdelzi as second-line or monotherapy based on data available since US approval in late 2024. Reductions in alkaline phosphatase (ALP) were observed in both groups, with most patients achieving ALP levels below...
system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB).
vaccines, and is expanding its global presence with successful US market entry of Alyglo™(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by...
most rapidly advancing biosimilar medicines portfolio, with 11 biosimilars approved and available around the world. In 2024, the company achieved record-breaking sales of KRW 1.5377 trillion and operating profit of KRW 435.4 billion. Samsung...
available in several countries within Europe from March 2023. OPUVIZ (aflibercept) was approved by the EC in November 2024 and by the Medicines and Healthcare products Regulatory Agency (MHRA) in April 2025 for the treatment of patients with Wet...
biotech firms. The company was acquired by Sanofi in 2009, gaining global recognition as a trusted vaccine supplier. In 2024, Shantha's facilities including Shanchol®, were acquired by GCBC Vaccines Pvt. Ltd. Today Shantha's legacy is continued,...
†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). About iCRYO Founded in 2015, iCRYO’s mission is to elevate the quality of life of its team members, guests,...
for the treatment of early Alzheimer's disease by the National Medical Products Administration (NMPA) in China. In January 2024, lecanemab was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI)...
trials conducted by Alteogen Biologics in 12 countries, including Europe, South Korea and Japan from June 2022 to February 2024. The comparative clinical evaluation involving 431 wAMD patients demonstrated that EYLUXVI®'s efficacy and safety are...
from a reputed global consulting firm. 2Among the Top 10 Professional Skin Care Brands in the U.S., according to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.). About Waldencast: Founded by Michel Brousset and Hind...
Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply. In August 2024, the global co-development and co-commercialization agreement was expanded to include gocatamig (MK-6070/DS3280), which...
facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated in December 2024. With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL, making it the single...
it from existing therapies. This milestone follows the FDA’s designation of VTB-10 as an Orphan Drug (ODD) in November 2024, enabling VASTHERA to formally begin global clinical development. The program has been supported by national funding from...
parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site...
Market: According to Grand View Research, the global obesity therapeutics market is valued at 15.9 billion US dollars in 2024 and is projected to grow to 60.5 billion US dollars by 2030. Currently, therapeutic and safety advantages in the GLP-1...
The Company is developing orticumab for secondary prevention of cardiac events after acute coronary syndrome (ACS). In 2024, Abcentra published promising clinical data from a phase 2a pilot study, which established clinical proof-of activity of...
ophthalmic solution was approved as dry eye drug therapy in the United States and in Canada in May 2023 and September 2024, respectively. About Hengrui Pharma: Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative, global...
the development of optimized outpatient care models. Additionally, "Guidelines for the Diagnosis and Treatment of Obesity (2024 Edition)" recommended pharmacotherapy when lifestyle interventions fail to meet weight loss goals. The "Guidelines for...
